Home › Calculator › BNTX Dividend Calculator 2026
BNTX Dividend DRIP Calculator 2026
1.93% YieldHealthcareBioNTech SE · NASDAQ
Price: $103.76 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BNTX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BNTX snowball 📈
$10,000 in BNTX → $10.44M in 10 years · $16.37/month
About BioNTech SE (BNTX) — Dividend Analysis 2026
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Compare BNTX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BNTX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BNTX position with:
🌍 BNTX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BNTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.93% | -0.87% | $193 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.64% | -1.16% | $164 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.54% | -1.26% | $154 / yr |
| 🇬🇧 UK ISA | 0% | 1.93% | -0.87% | $193 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.76% | -1.04% | $176 / yr |
| 🇨🇦 TFSA | 0% | 1.93% | -0.87% | $193 / yr |
| 🇨🇦 CA Taxable | 25% | 1.45% | -1.35% | $145 / yr |
| 🇦🇺 Super (pension) | 15% | 1.64% | -1.16% | $164 / yr |
| 🇦🇺 AU Taxable | 30% | 1.35% | -1.45% | $135 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.42% | -1.38% | $142 / yr |
| 🇫🇷 FR Taxable | 30% | 1.35% | -1.45% | $135 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BNTX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BNTX Dividend Payment Schedule
BNTX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BNTX vs Healthcare Benchmarks
How BNTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BNTX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BNTX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-09-03 | 45,000 | $102.85 | $4.63M | ||
| Sale | 2026-09-04 | 31,500 | $103.52 | $3.26M | ||
| A-Award | 2026-05-12 | 18,879 | — | — | ||
| A-Award | 2026-05-12 | 15,103 | — | — | ||
| A-Award | 2026-05-12 | 12,586 | — | — | ||
| A-Award | 2026-05-12 | 10,069 | — | — | ||
| A-Award | 2026-05-12 | 12,586 | — | — | ||
| A-Award | 2026-05-12 | 10,069 | — | — | ||
| A-Award | 2026-05-12 | 10,488 | — | — | ||
| A-Award | 2026-05-12 | 8,391 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where BNTX earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BNTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
BioNTech SE (BNTX) is currently trading at $103.76, 70% below its 52-week high. The current dividend yield is 1.93% based on an annual payout of $2.00 per share.
BNTX (BioNTech SE) — 1.93% Dividend Yield Analysis
BioNTech SE (BNTX) is a healthcare stock currently trading at $103.76 with a dividend yield of 1.93%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.